Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

December 27, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

February 28, 2028

Conditions
Malignant MesotheliomaMetastatic Malignant Solid TumorAdvanced Solid Tumor
Interventions
DRUG

ISM6331

"Dosage form: Capsule for oral administration.~Frequency of administration: Once daily overall of treatment."

Trial Locations (9)

19104

RECRUITING

University of Pennsylvania - Abramson Cancer Center, Philadelphia

37203

RECRUITING

SCRI Oncology Partners, Nashville

44106

RECRUITING

University Hospitals Cleveland Medical Center, Cleveland

60637

RECRUITING

The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago

78758

RECRUITING

NEXT Oncology - Austin, Austin

80218

RECRUITING

Sarah Cannon Research Institute at HealthONE, Denver

Unknown

RECRUITING

Henan Cancer Hospital, Zhengzhou

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

RECRUITING

Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

InSilico Medicine Hong Kong Limited

INDUSTRY